Supernus Pharmaceuticals (SUPN) closed at $40.70 on October 23, 2026, down 3.3% from the previous close, on volume of 1,107,405 shares (30-day average 796,708).
Data as of October 23, 2026.
23-Oct-2026
MSG Rangers and Huron Consulting Group to join S&P SmallCap 600
Seeking Alpha News (Fri, 23-Oct 1:19 AM ET)
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
PRNewswire (Thu, 22-Oct 6:09 PM ET)
Supernus Gains Orphan Exclusivity for ONAPGO Parkinson’s Therapy
TipRanks (Thu, 22-Oct 6:33 AM ET)
Supernus Announces Orphan Drug Exclusivity for ONAPGO (apomorphine HCl)
Globe Newswire (Wed, 21-Oct 7:45 PM ET)
Supernus Pharmaceuticals (SUPN) Gets a Buy from TD Cowen
TipRanks (Wed, 21-Oct 8:57 AM ET)
Globe Newswire (Mon, 19-Oct 8:30 AM ET)
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 25-Sep 7:38 AM ET)
Business Wire (Thu, 24-Sep 5:16 PM ET)
Supernus Pharmaceuticals to Participate in September Investor Conferences
Globe Newswire (Wed, 2-Sep 4:30 PM ET)
Globe Newswire (Mon, 31-Aug 8:30 AM ET)
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Supernus Pharmaceuticals trades on the NASDAQ stock market under the symbol SUPN.
As of October 23, 2026, SUPN stock price declined to $40.70 with 1,107,405 million shares trading.
SUPN has a beta of 1.11, meaning it tends to be more sensitive to market movements. SUPN has a correlation of 0.16 to the broad based SPY ETF.
SUPN has a market cap of $2.37 billion. This is considered a Mid Cap stock.
Last quarter Supernus Pharmaceuticals reported $219 million in Revenue and $.53 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.11.
In the last 3 years, SUPN traded as high as $59.68 and as low as $21.99.
The top ETF exchange traded funds that SUPN belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
SUPN has underperformed the market in the last year with a price return of -19.7% while the SPY ETF gained +14.9%. SUPN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.3% and -3.4%, respectively, while the SPY returned +1.9% and -1.8%, respectively.
SUPN support price is $40.92 and resistance is $43.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SUPN shares will trade within this expected range on the day.
